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Abstract The aim of the study was to determine the
economical impact of juvenile idiopathic arthritis (JIA) and
familial Mediterranean fever (FMF) in Turkey. A total of
100 patients (69 F/31 M) with JIA and 100 with FMF (68
F/32 F) who were consecutively seen in the outpatient
clinic of the pediatric rheumatology department at
Cerrahpasa Medical School between August 2008 and
January 2009 were studied. Cost data were collected
through a questionnaire ﬁlled out by the parents. The mean
age (JIA: 11 ± 5 years; FMF:12 ± 4 years) and mean
disease duration (JIA:5 ± 3 years; FMF: 4 ± 3 years) of
the patients were similar. JIA patients were assigned to 5
subtypes (polyarticular: n = 45, oligoarticular: n = 30,
systemic onset: n = 13, psoriatic: n = 6, and enthesopa-
thy-related JIA: n = 6). Forty-nine percent of the patients
with JIA were treated with anti-TNF drugs and 61% with
DMARDs. All patients with FMF were using colchicine.
The total annual cost of JIA (€3,994 ± 4,101) was con-
siderably higher than that of FMF (€162 ± 77)
(P\0.001). Medication fee was the major determinant of
total costs in both diseases constituting 85% in JIA and
39% in FMF. Among the subtypes of JIA, total annual
costs were the highest among patients with polyarticular
type (€6,045 ± 4,078). Medications especially anti-TNF
drugs were the major contributor among all determinants of
costs in JIA. The low costs of health care system and
prominent changes in the health care policies for the last
5 years in Turkey might have played role in our ﬁndings.
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Juvenile idiopathic arthritis (JIA) is the most common
rheumatic disease in childhood [1]. It is a debilitating
chronic disease with considerable morbidity and mortality.
Multidisciplinary management of the patients with frequent
hospital visits accompanied by various medical and phys-
ical treatments results in considerable economic burden on
the health care system. Widespread use of anti-TNF agents
causes further increments in the costs. Moreover, economic
burden of the disease may extend into the adulthood [2].
Despite all these, studies investigating the economic
impact of JIA are limited in number [2–7] and few [4, 5, 7]
sought the cost of biological therapies.
Familial Mediterranean fever (FMF), on the other hand,
is an autoinﬂammatory disease common in eastern Medi-
terranean populations [8]. It is characterized by self-limited
episodes of fever, serosal and synovial inﬂammation such
as peritonitis, pleuritis, and arthritis, as well as myalgia and
erysipelas-like erythema [8, 9]. Amyloidosis leading to
chronic renal failure is its most severe complication,
developing in 10–15% of patients [8]. FMF can be asso-
ciated with necrotizing vasculitis, ankylosing spondylitis,
and chronic inﬂammatory bowel diseases. Apart from these
associations, it has no apparent morbidity and causes no
disability and usually treated with colchicine alone. To our
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has been done before.
In this study, we aimed to estimate the economic burden
of patients with JIA attending a pediatric tertiary referral
center in Istanbul, Turkey and as the control group we used
patients with FMF.
Patients and methods
We studied consecutive patients with JIA and FMF who
were seen in the pediatric rheumatology outpatient clinic of
Cerrahpasa Medical Faculty at the University of Istanbul
between August 2008 and January 2009. Patients with JIA
were diagnosed according to ILAR criteria [10] and
assigned to a subtype. However, due to small number in
each group we had to accumulate the patients into 5 main
clinical types. Patients with FMF fulﬁlled the Livneh
diagnostic criteria [11]. Only patients with at least 1 year
of diagnosis were included in the study.
Disease characteristics, laboratory data, and drug
information were obtained form the patient’s charts.
Functional limitation of patients with JIA was assessed by
using Childhood HAQ (CHAQ) score at the time of the
study entry. The parent (if the child\8 years old) or the
child (if the child C 8 years old) completed a CHAQ val-
idated for use in the Turkish population [12].
Patients with JIA are seen routinely every 3 months in
the outpatient unit; however, visits can be more frequent if
necessary. In each visit, laboratory tests (ESR, whole blood
count, liver tests and urine dipstick test) were done.
Physiotherapy is also given as part of the management and
decision as to whether splints/devices are necessary is
taken in the same unit. Patients with FMF, however, are
seen twice a year in the outpatient clinic. Laboratory tests
that are requested in each visit are whole blood count, ESR,
and urine dipstick test.
Socioeconomic evaluation
Data on demographic, educational, and employment status
of parents were obtained by questionnaire. Five variables
were used to measure socioeconomical status: education,
occupation, monthly family income, wealth score, and sum
of the household members. Wealth score was calculated by
summing the items/goods or proprieties found in the indi-
vidual or household’s possession. The items were tele-
phone, mobile telephone, washing machine, dishwasher,
personal computer, house, summer house, and car. Each
item was scored as 1 point, giving the range of WS
between 0 and 8.
Resource use and cost assessment
The information on expenses directly or indirectly related
to the disease within the preceding 3 months was collected
by interviewing parents with the help of a structured
questionnaire. Twelve-month costs were estimated multi-
plying these data by 4. All costs were converted into euro
(€) using the purchasing power parity value of Turkey as of
January 2009 (1 € = 2.15 YTL).
The unit price of each service (outpatient visits and
blood, biochemistry, and radiological tests) was deter-
mined according to the price list set by the Cerrahpasa
Medical Faculty.
Other outpatient visits such as physiotherapy, ophthal-
mology, endocrinology, or emergency and private practice
visits are priced according to price set by each relevant
facility. Physician visits not related to JIA or FMF are
excluded from the analyses. Hospitalization costs were
estimated for the 12 months prior to study entry. Infor-
mation related to type and dose of the medications was
obtained from patient’s charts. The costs of the drugs were
obtained from the price list set by the Turkish Ministry of
Health. Costs of generic drugs were used.
Medications used in the treatment of patients with JIA
were ibuprofen, indomethacin, prednisolone, methotrexate
(MTX), sulphasalazine (SAZ), cyclosporine (CSA), eta-
nercept (Enbrel), inﬂiximab (Remicade), gastroprotective
agents, calcium, vitamin D, and biphosphonate. Patients
with FMF were treated with colchicine.
Costs of splinting, devices, and aids were estimated
considering those used for the preceding 12 months.
Non-health care costs
Non-health care costs covered 3 months and included
disease-related expenditure like transport and lodging and
domestic help.
Indirect costs
Indirect costs were evaluated by considering parents’ time
away from paid work due to children’s disease (JIA and
FMF). An estimate of the loss of productivity was obtained
by multiplying the cumulative number of work days lost
over the preceding 3 months by 4 and by the individual
daily wage of the parent.
Social security system in Turkey
The study was done after the uniﬁcation of the social
security system in Turkey by law on March 2006 [13–15].
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servants, contractual paid workers, agricultural paid
workers, self-employers, and agricultural self-employers
into one to offer equal actuarial rights and obligations. By
this law, all children under 18 years old who are not con-
sidered as insurance holders or are not holders of voluntary
insurance are under the coverage of social security insti-
tution [16]. All health expenditures including hospitaliza-
tion, laboratory tests, investigations, hospital visits, and
medications are fully reimbursed.
Ethic committee of the Cerrahpasa Medical Faculty
approved the study, and oral informed consent was taken
from the parents before each interview.
Statistical analysis
Continuous variables with a normal distribution were
expressed as means ± SDs and others with non-normal
distribution as medians and interquartile ranges [IQR].
Categorical variables were compared using the chi-square
test or Fisher’s exact tests. Comparisons of continuous
variables were made by using Student’s t tests and one-way
ANOVA followed by Tukey HSD test. Demographic,
clinical, and socioeconomical variables that are associated
with cost were determined ﬁrst by univariate analysis
than tested with multiple logistic regression analyses.
Independent variables that were used in these analyses
were gender, age, disease duration, wealth score, CHAQ
score, ANA and RF positivity, and JIA subgroups. Total
annual cost was dichotomized into high and low cost as
upper and lower of the median value of €2,345 for JIA and
used in the multiple regression tests. All statistical analyses
were carried out using statistical software (SPSS, version
13.0 for Windows; SPSS, Chicago, IL).
Results
Patient demographics, clinical characteristics,
and socioeconomic status
We studied 100 (31 M/69 F; mean age: 10.5 ± 4.6 years)
patients with JIA and 100 (32 M/68 F; mean age:
11.5 ± 4.1 years) patients with FMF. Table 1 shows
demographic characteristics and socioeconomic status of
the study participants (Table 1). Patients with JIA were
more likely to have longer disease duration and less likely
to live in Istanbul compared to patients with FMF. Parental
education, occupation status, and social security types did
not differ among those with JIA and FMF. Fathers of 2
patients with JIA and one with FMF had deceased. Patients
with JIA had signiﬁcantly lower wealth score and higher
total count of household members compared to patients
Table 1 Demographic
characteristics and
socioeconomic status of patients
a Fathers of 2 patients with JIA
and one with FMF had deceased
JIA (n = 100) FMF (n = 100) P
Female, n (%) 69 (69) 68 (68) 0.879
Age, mean ± SD, years 10.5 ± 4.6 11.5 ± 4.1 0.082
Disease duration, mean ± SD, years 5.3 ± 3.4 4.4 ± 3.4 0.056
Istanbul, n (%) 77 (77) 89 (89) 0.024
Parental employement status
a, n (%)
Professional (like lawyer, doctor,
teacher, architect…) or director
6 (3) 4 (2) 0.781
Ofﬁce worker 15 (8) 21 (11)
Unskilled worker 78 (39) 70 (35)
Retired 9 (15) 15 (8)
Unemployed 3 (1) 5 (3)
Housewife 87 (44) 84 (42)
Parental education
a, n (%) 0.90
None 13 (7) 12 (6)
Primary school 138 (69) 140 (70)
High school 29 (15) 28 (14)
University 18 (9) 20 (10)
Social security, n (%) 100 (100) 98 (98) 0.136
Total count of household members, mean ± SD 5.0 ± 1.4 4.3 ± 1.0 \0.001
Monthly income per family in €, mean ± SD 644 ± 243 672 ± 310 0.479
Wealth score, mean ± SD 4.8 ± 1.6 5.4 ± 1.5 0.011
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patients. The mean monthly income per family was similar
between two study groups (Table 1).
ESR and counts of white blood cells (WBC) and
platelets (PLT) were signiﬁcantly higher among patients
with JIA compared to those with FMF, indicating a higher
inﬂammatory state among patients with JIA (ESR:
32.0 ± 22.1 vs. 21.1 ± 14.1 mm/h, P\0.001; WBC:
9,672 ± 3,649 vs. 7,983 ± 2,859, P\0.001; PLT:
379.150 ± 124.729 vs. 298.020 ± 83.412, P\0.001, for
JIA vs. FMF, respectively). However, hematocrite level
was similar between the study groups (36.4 ± 3.4% vs.
36.8 ± 3.2%, P = 0.434).
The patients with JIA were divided into 5 clinical
subgroups as shown in Table 2. Polyarthritis patients
(n = 45) were in the majority followed by oligoarthritis
(n = 30), systemic (n = 13), psoriatic arthritis (PsA)
(n = 6), and enthesitis-related arthritis (ERA) patients
(n = 6). Except patients with ERA, patients with JIA
were more likely to be women (Table 2). Patients with
polyarthritis type and those with ERA were signiﬁcantly
older compared to the rest of the group. Disease duration
was signiﬁcantly longer among patients with polyarticular
JIA compared to those with oligoarthritis. CHAQ scores
did not differ between the subgroups of JIA (Table 2) and
similarly, there was no signiﬁcant difference between the
subgroups of JIA with regard to ESR and whole blood
counts (data not shown). By deﬁnition, the frequency of
uveitis and positivity for ANA, RF, and HLA-B27 were
signiﬁcantly different between the subgroups of JIA
(Table 2).
Resource consumption
As seen in Table 3, use of health care services per
3 months such as outpatient visits and biochemical and
radiological tests was signiﬁcantly more common among
patients with JIA compared to patients with FMF. None of
the parents had needed domestic help and care for the
patients.
Table 2 Clinical characteristics of patients with juvenile idiopathic arthritis (JIA) according to subgroups
Polyarthritis
(n = 45)
Oligoarthritis
(n = 30)
Systemic
arthritis
(n = 13)
Psoriatic
arthritis
(n = 6)
Enthesitis-related
(n = 6)
P
Female, n (%) 31 (69) 26 (87) 8 (62) 4 (67) 0 0.001
a,b,c,d
Age, mean ± SD, years 12.3 ± 4.4 8.0 ± 3.2 8.5 ± 5.3 8.8 ± 3.1 14.2 ± 3.0 \0.001
b,c,e,f
Disease duration, mean ± SD, years 6.6 ± 3.7 3.8 ± 2.3 5.3 ± 3.6 5.1 ± 3.4 4.2 ± 2.6 0.01
e
CHAQ, mean ± SD 0.30 ± 0.50 0.10 ± 0.21 0.16 ± 0.35 0.26 ± 0.61 0.23 ± 0.46 0.352
ANA (?), n (%) 11 (24) 22 (73) 2 (15) 2 (33) 0 \0.001
a,b,c,d
Uveitis (?), n (%) 0 4 (13) 0 0 0 0.045
RF (?), n (%) 11 (24) 1 (3) 3 (23) 2 (33) 0 0.077
HLA B 27 (?), n (%) 0 0 0 0 6 (100) \0.001
a,b,c,d
a Enthesitis-related versus Polyarthritis;
b Enthesitis-related versus oligoarthritis;
c Enthesitis-related versus systemic arthritis;
d Enthesitis-
related versus psoriatic arthritis;
e Polyarthritis versus oligoarthritis;
f Polyarthritis versus systemic arthritis
Table 3 Use of health care
services and parental work
day loss per 3 months
JIA Juvenile idiopathic arthritis,
FMF Familial Mediterranean
fever
JIA, n = 100 FMF, n = 100 P
Outpatient visits, mean ± SD 2.9 ± 1.0 1.0 ± 0.4 \0.001
Biochemical tests, mean ± SD 5.9 ± 0.8 4.3 ± 0.4 \0.001
Radiological tests, n (%) 24 (24) 5 (5) \0.001
Physiotherapy, n (%) 36 (36) 0 \0.001
Splints/braces, n (%) 7 (7) 0 0.007
Hospitalization, n (%) 5 (5) 2 (2) 0.445
Duration of hospitalization, mean ± SD, days 12.8 ± 12.9 5.5 ± 6.4 0.496
n who had underwent surgical operation, n (%) 1 1 1.0
Duration of hospitalization for surgery, days 1 2 1.0
n of parents with work day loss, n (%) 24 (24) 10 (10) 0.008
Work days lost among parents, mean ± SD, days 2.75 ± 3.03 1.10 ± 0.32 0.014
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Parents who had work day loss and mean lost workdays
due to the child’s disease during a period of 3 months were
signiﬁcantly higher among patients with JIA compared to
those with FMF (Table 3).
Medications
Atotalof86(86%)patients with JIAusedDMARDs(MTX,
CSA and SAZ) and or anti-TNF agents along with cortico-
steroidsandNSAIDs.Prednisolone(58%),MTX(58%),and
etanercept (47%) were the most frequently used drugs, fol-
lowed by calcium tablets (27%), gastroprotective agents
(22%), NSAIDs (12%), CSA (4%), inﬂiximab (2%), and
SAZ (2%). The remaining 14% were off treatment. The
mean dose of MTX was 14.3 ± 6.5 mg/week and that of
prednisolone was 8.1 ± 6.7 mg/day. The etanercept dose
was 25 mg once a week in 25 patients, twice a week in 11
others, 20 mg per week in 5, and 15 mg per week in the 6
remaining patients.
When subgroups of JIA were analyzed separately, it was
seen that etanercept was most commonly used by polyar-
thritis group (73%) followed by PsA (50%), ERA (33%),
systemic arthritis (23%), and oligoarthritis (20%)
(P\0.001). There were only two patients with JIA who
were treated with inﬂiximab (polyarthritis: 1 and oligoar-
thritis: 1). SAZ was used only by patients with ERA (2/6).
The use of other medications did not differ signiﬁcantly
between the subgroups. All FMF patients were using col-
chicine (100%) and very few NSAIDs (8%).
Mean annual total costs and its components (Table 4)
The mean annual total cost for the JIA cohort was esti-
mated to be €3,994 ± 4,101. The mean direct costs were
98% of the total costs. Almost 85% of the total costs were
incurred by the drugs (€3,381 ± 3,881), 76% being just by
anti-TNF agents (€2,959 ± 3,483). All other health care
costs including outpatient visits (1.4%), biochemical tests
(5.4%), radiological investigations (0.3%), devices (0.3%),
physiotherapy (0.5%), hospitalization (0.6%), and surgeries
(0.06%) accounted for only 8% of the total costs. Trans-
portation and lodging expenses made 4.7% of the total
costs.
The mean annual total cost for FMF was calculated as
162 ± 77 €. As in JIA, the mean direct costs were 98% of
the total costs and medications were the largest contributor
to total costs (39%) in the FMF cohort. Biochemical/
radiological tests (32%), transportation and lodging (13%),
outpatient visits (9%), hospitalization and surgery (5%),
and lost wages (2%) were other contributors to the total
costs in FMF. The mean annual total costs and almost all
components of the total cost were found to be signiﬁcantly
lower in FMF compared to the JIA cohort (Table 4).
In each subtype of JIA, the largest contributor to the
total costs was still the costs of medications, especially that
of anti-TNF drugs. Among all subtypes, polyarthritis type
had the highest total (6,045 ± 4,078 €) and anti-TNF drug
costs (4,770 ± 3,514 €) followed by (in descending order)
ERA (total costs: 4,828 ± 6,228 €, anti-TNF drugs:
2,625 ± 4,393 €), PsA (total: 3,219 ± 3,091 €, anti-TNF
drugs: 2,450 ± 2,711 €), oligoarthritis (total: 1,857 ±
2,836 €, anti-TNF drugs: 1,239 ± 2,547 €), and systemic
arthritis (1,795 ± 2,269 €, anti-TNF drugs: 1,050 ±
2,056 €).
Total costs of those who were treated with anti-TNF
drugs (n = 49) were estimated as €7,530 ± 2,984, whereas
that of those who were treated without anti-TNFs (n = 51)
were calculated as 595 ± 846 €. While drug costs made
90% of the total costs in the anti-TNF group, transportation
and lodging expenses (35%) made the major contribution
Table 4 Mean annual costs and
its components for patients with
JIA and FMF (€)
JIA Juvenile idiopathic arthritis,
FMF Familial Mediterranean
fever
JIA (n = 100) FMF (n = 100) P
Direct costs 3,913 ± 4,024 159 ± 76 \0.001
Outpatient clinic visits 55 ± 29 15.3 ± 4 \0.001
Biochemical tests 216 ± 119 50 ± 7 \0.001
Radiological tests 11 ± 39 2 ± 15 0.039
Drugs 3,381 ± 3,881 63 ± 16 \0.001
Anti-TNF agents 2,959 ± 3,483 0 \0.001
Others 422 ± 760 63 ± 16 \0.001
Devices 12 ± 52 0 0.029
Physiotherapy 21 ± 66 0 0.001
Hospitalization fees 27 ± 189 4 ± 33 0.248
Surgeries 3 ± 26 4 ± 40 0.767
Transportation and lodging expenses 188 ± 562 21 ± 39 0.004
Indirect costs 81 ± 257 3 ± 14 0.003
Total costs 3,994 ± 4,101 162 ± 77 \0.001
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medications (20%) in the other.
Variables associated with high cost among patients
with JIA (Table 5)
As shown in Table 5, increased age, long disease duration,
highwealthscores,highCHAQscores,ANAnegativity,and
havingapolyarthritistypeofJIAwerefoundtobeassociated
with high total cost. In addition, JIA patients with RF (?)
tended to have higher costs compared to those with RF (-).
Multiple regression analyses showed that having a polyar-
thritis type of JIA (OR: 6.0, 95% CI: 2.0–17.5, P = 0.001),
high CHAQ scores (OR: 3.5, 95% CI: 1.2–10.3, P = 023),
ANAnegativity(OR:3.3,95%CI:1.0–10.2,P = 0.04),and
highwealthscores(OR:0.3,95%CI:0.09–0.78,P = 0.016)
were independently associated with high costs.
Discussion
In this study, the mean annual total cost of JIA in Turkey
was estimated as €3,994 ± 4,101. Cost of medications
(85%), especially that of anti-TNF agents (76%), made the
largest contribution to the total cost. Among the subtypes
of JIA, polyarthritis type had the highest cost. Meanwhile,
the control group FMF was found to have a modest total
annual cost (€162 ± 77).
The main results of the 5 JIA costing studies published
within the last 6 years are summarized in Table 6 [2, 4–7].
As there are great variances with regard to the health care
systems, methodologies, patient characteristics, frequency
of DMARDs and anti-TNF use, caution is required while
comparing each other. Minden et al. in their ﬁrst study
assessed costs of JIA patients in the adulthood and found
that 55% of the patients had still active disease after
17 years of disease onset [2]. The costs due to loss of
productivity made 45% of the total costs in contrast to
other studies including ours [4–7]. In their second study,
Minden et al. assessed the costs in a younger JIA cohort
[7]. They observed that health care costs accounted for
89% of total costs and medications contributed to half of
this value [7]. The Finnish study evaluated especially the
costs of etanercept addition to the prevailing drug therapy
for a 1-year period [4]. While total median costs amounted
to $7,732 by the end of the year, the median direct costs per
patient was increased by about $2,700. However, authors
observed a 50% drop in the indirect costs [4]. Bernatsky
et al. showed that direct costs for children with JIA ($3002
Canadian dollars) were higher than that for children with-
out chronic disease ($1,686 Canadian dollars), particularly
due to medication costs [5]. Thornthon et al. observed
direct costs of JIA patients speciﬁcally in the ﬁrst year of
their diagnosis and found that the highest cost component
was appointments with pediatric rheumatologists [6]. There
is also another study that was done in the United States by
Allaire et al. about two decades ago when biologics were
not introduced and therapy with DMARDs was a new
notion [3]. The mean annual direct cost per child was
estimated as $7,905, annual family costs averaged $1,524
and medications contributed to only 7% of the health care
costs [3].
Drugs are currently the main cost driver in rheumatoid
arthritis [17, 18] and in most JIA costing studies including
ours [4, 5, 7] as shown in Table 6. However, data about the
use of DMARDs and biologics were not sufﬁcient in these
studies, despite the fact that most of them dated relatively
to a recent period. Of the 5 studies, 3 did not determine
DMARD use and 2 did not specify biologics use [2, 4, 6].
Moreover, of the remaining studies, in one, only about
1/3rd of the patients used DMARDs [5] and in 2, biological
use was present in the minority of patients [5, 7]. The rate
of DMARD use (61% vs. 68%) was similar, however, that
of biological use was substantially higher in our study
compared to the recent German study (49% vs. 6%,
respectively) [7]. This is most probably due to the great
Table 5 Variables associated with costs among patients with juve-
nile idiopathic arthritis (JIA)
N Mean ± SD costs P
Gender
Female 69 3,721 ± 3,699 0.325
Male 31 4,589 ± 4,893
Age
2–9 years 42 1,926 ± 2,533 \0.001
C10 years 58 5,490 ± 4,378
Disease duration
1–4 years 49 2,710 ± 3,166 0.002
C5 years 51 5,226 ± 4,529
Wealth score
1–4 43 2,549 ± 2,875 0.001
5–8 57 5,083 ± 4,552
ANA (?)
Yes 37 2,106 ± 3,202 \0.001
No 63 5,102 ± 4,186
RF (?)
Yes 17 5,632 ± 4,406 0.07
No 83 3,658 ± 3,981
CHAQ score
0 54 2,915 ± 3,913 0.004
[0 46 5,259 ± 3,992
JIA subtype
Polyarticular type 45 6,045 ± 4,078 \0.001
All other types 55 2,315 ± 3,303
1960 Rheumatol Int (2012) 32:1955–1962
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therapeutic approaches. Reimbursement by the health
insurance systems may also play role. It is also to be noted
that, although patients are included in a consecutive man-
ner in the study, those who use anti-TNFs may tend to
attend the outpatient clinic more frequently than those who
do not use. Therefore, the current study may not represent
the actual anti-TNF use in our center.
While medication was the major contributor to the
health care cost, its share was almost 50% in most of the
JIA costing studies [4, 5, 7]. However, in our study, this
was 90%. Similarly, contribution of medications was cal-
culated as 78% in another cost of illness study done for
Behc ¸et’s syndrome again in our institution [19]. In fact,
when the costs for laboratory tests and devices were
excluded, costs for inpatient and outpatient care, which
also included physician visits, rheumatology consultations,
physiotherapy, and nurse care, altogether made only 3% of
the health care costs in JIA. This negligible share is the
result of the low cost of health care system in Turkey.
Prominent changes in the health care policies for the last
5 years as part of a health reform program helped more in
the minimization of this share [14, 15]. The reform pro-
gram, which had aimed making health care available to a
larger share of the population, caused much controversy.
Decrease in the quality of the health care is one of its
drawbacks.
Similar to what was reported in previous studies [2–7],
we also showed that JIA causes considerable economic
burden for the health care system in Turkey. However, with
such a high rate of anti-TNF use at hand, one might have
expected much increased total costs if the study had been
done in Finland or Germany. This is, as mentioned earlier,
due to low priced health care system in our country.
FMF is one of the most common disease in Turkey with
a prevalence rate amounting to 0.9% [20, 21]. Our study is
the ﬁrst to assess socioeconomic status and economic
impact of juvenile patients with FMF. While socioeco-
nomic status was found to be more favorable, total costs
were signiﬁcantly lower in patients with FMF compared to
those with JIA. Certain diseases such as asthma, coronary
atherosclerosis, systemic lupus erythematosus, and Be-
hc ¸et’s syndrome have been reported to be more frequent in
lower socioeconomic classes [22–25]. Furthermore,
socioeconomic status and education may have impact on
disease outcome [26]. On the other hand, this issue seems
to be controversial for JIA, since one study from Denmark
reported that children whose parents had a high income had
a 2 times greater risk of developing JIA compared to age
and sex matched controls [27]. It is also to be noted that,
our study may not be conclusive, since parents of FMF
patients may not represent general population in Turkey.
Moreover, high wealth score was a predictor of high costs
for JIA patients in our study, a fact supporting the Danish
study.
This study has some limitations. Sample size of JIA
subgroups was small and we did multiple comparisons;
therefore, caution is needed in interpretation the results.
Our ﬁndings are subject to recall bias because of the
methodology used; similar to most cost of illness studies,
our study was retrospective taking into account preceding
3 months. We did not evaluate missed school days of the
Table 6 Cost of illness studies in Juvenile Idiopathic Arthritis (JIA)
Author (ref. no),
publication date,
country
Minden et al. [2]
2004, Germany
Haapasaari et al. [4]
2004,
Finland
Bernatsky et al.
[5] 2007,
Canada
Thornton et al. [6]
2008, England
Minden et al. [7]
2009, Germany
Current study,
Turkey
Years evaluated 1998–2000 1999–2000 2005 2005 2003 2008–2009
n 215 31 155 297 369 100
Female 116 (54%) Not speciﬁed 108 (70%) 191 (64%) 263 (71%) 69 (69%)
Age, years 23 10 10 8.2 ± 4.3 12 10.5 ± 4.6
Disease duration,
years
17 6 4.3 1 5 5.3 ± 3.4
DMARD use Not speciﬁed Not speciﬁed 39% Not speciﬁed 242 (68%) 61 (61%)
Biological drug
use
Not speciﬁed 100% 8 (5%) Not speciﬁed 20 (6%) 49 (49%)
Costs Total cost:
€3,471 ± 9,032
Total cost: median
$7,732
Direct cost:
$3,002
Direct cost:
€2,391 ± 1,585
Total cost:
€4,663 ± 6,928
Total costs:
€3,994 ± 4,101
Largest contributor
to cost
Inpatient and
outpatient
health
care services
Medications
(etanercept)
Medications Appointments for
pediatric
rheumatologists
Medications Medications
Direct costs/total
costs
55% 95% Not applicable Not applicable 94% 98%
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123patients. As part of out-of-pocket expenses we assessed
only transportation and lodging expenses during the hos-
pital visits and cost for any domestic help. Finally, since
our study was done in Turkey and in a tertiary referral
center, our results must not be generalized.
Conclusions
Our study is the ﬁrst to estimate the direct and indirect
costs for JIA and FMF in Turkey. The mean annual total
cost of JIA was calculated as €3,994 ± 4,101 and that of
FMF as €162 ± 77. More severe disease subtype and poor
function incurred higher costs in JIA. Medications, par-
ticularly anti-TNF agents (76%), were the major cost dri-
ver. Health care costs other than drugs were almost
negligible. JIA imposes a substantial economic burden for
the health care system in Turkey; however, considering the
high rate of anti-TNF use, its burden is substantially lower
compared to what was estimated in other countries.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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